In the latest trading session, Pfizer (PFE) closed at $22.15, marking a +0.48% move from the previous day. The stock exceeded the S&P 500, which registered a gain of 0.13% for the day. On the other ...

We recently published a list of 15 Best Large-Cap Value Stocks to Buy as the Recession Hits. In this article, we are going to take a look at where Pfizer Inc. (NYSE:PFE) stands against other best ...

Pfizer's strong R&D pipeline, 7.5%+ dividend yield, & undervalued PE ratio make PFE stock a compelling investment opportunity ...

Tuesday was a relatively uneventful news day for Pfizer, especially following the pharmaceutical giant's disclosure on Monday ...

Its statement also suggested the patient’s liver enzymes were elevated. That often is indicative of damage to cells in the organ, according to the Cleveland Clinic. Pfizer told CNBC that the trial ...

Pfizer Inc. (PFE) is currently at $22.83, up $0.71 or 3.19% --Would be highest close since April 4, 2025, when it closed at $22.97 --On pace for largest percent increase since Dec. 17, 2024, when it ...

Pfizer (NYSE: PFE) recently reminded investors how risky the drug-development business can be. On April 14, the company told investors it would scrap development of danuglipron, its oral GLP-1 ...

TD Cowen analyst Steve Scala maintained a Hold rating on Pfizer (PFE – Research Report) today and set a price target of $32.00. The company’s ...

So far this year, Pfizer shares have dropped 17.4%, while Novo Nordisk's stock has tumbled 24% and Lilly shares have slipped 3.2%. The SPDR S&P Pharmaceuticals ETF XPH has shed 12.1% year to date and ...

What Happened? A number of stocks fell in the afternoon session after stocks gave back some of the gains from the previous ...

Five years ago, volunteers rolled up their sleeves in the first clinical trial of a vaccine against COVID-19, as the new ...

Pfizer stock shows strong potential with updates on danuglipron, robust cost controls, and attractive valuations. Learn more ...